Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Gilead Sciences (GILD) closed at $113.03 in the latest trading session, marking a -2.73% move from the prior day. This change lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw a ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Visa will report its fiscal third quarter financial results on Tuesday, July 29. Analysts expect the company to report quarterly earnings at $2.85 per share. That’s up from $2.42 per share in the year ...

The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...